EBS - Emergent Biosolutions EPS beats by $0.04 misses on revenue revised FY20 guidance

Emergent Biosolutions (EBS): Q3 Non-GAAP EPS of $2.19 beats by $0.04; GAAP EPS of $0.73 misses by $1.03.Revenue of $385.2M (+23.5% Y/Y) misses by $53.31M.FY2020 guidance: Total revenues of $1,520M-$1,580M from previous guidance of $1,500M-$1,600M vs consensus of $1.52B ; Adjusted net income of $375M-$405M from previous guidance of $340M-$390M; Adjusted EBITDA of $575M-$615M from previous guidance of $535M-$600M.Shares -4.7% AH.Press Release

For further details see:

Emergent Biosolutions EPS beats by $0.04, misses on revenue, revised FY20 guidance